MTOR
MOLECULAR TARGETmechanistic target of rapamycin kinase
MTOR (mechanistic target of rapamycin kinase) is targeted by 27 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MTOR
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Sirolimus | 3.87 | 47 |
| 2 | torin 1 | 3.26 | 25 |
| 3 | pictilisib | 2.94 | 18 |
| 4 | Everolimus | 2.83 | 16 |
| 5 | ly294002 | 2.83 | 16 |
| 6 | Ku 0063794 [Supplementary Concept] | 2.48 | 11 |
| 7 | Rotenone | 1.95 | 6 |
| 8 | Thapsigargin | 1.39 | 3 |
| 9 | Wortmannin | 1.39 | 3 |
| 10 | alpelisib | 1.10 | 2 |
| 11 | amn082 | 1.10 | 2 |
| 12 | Calcimycin | 1.10 | 2 |
| 13 | Idarubicin | 1.10 | 2 |
| 14 | Idazoxan | 1.10 | 2 |
| 15 | Niclosamide | 1.10 | 2 |
| 16 | triolimus [Supplementary Concept] | 1.10 | 2 |
| 17 | tyrphostin 9 | 1.10 | 2 |
| 18 | egcg | 0.69 | 1 |
| 19 | Ursolic Acid | 0.69 | 1 |
| 20 | Camptothecin | 0.69 | 1 |
| 21 | Dequalinium | 0.69 | 1 |
| 22 | Disulfiram | 0.69 | 1 |
| 23 | Emetine | 0.69 | 1 |
| 24 | Epinephrine | 0.69 | 1 |
| 25 | Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on | 0.69 | 1 |
| 26 | Maprotiline | 0.69 | 1 |
| 27 | Perphenazine | 0.69 | 1 |
About MTOR as a Drug Target
MTOR (mechanistic target of rapamycin kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 27 compounds with documented MTOR interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MTOR inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.